Zydus Lifesciences Limited reported a 30 per cent year-on-year increase in net profit to ₹1,023.5 crore for the quarter ended December 31, 2024, driven by robust performance in its US ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

(Image Credits: Pixabay) Zydus Lifesciences Ltd on Wednesday reported a profit of Rs 1023.80 crore during the third quarter of FY25, posting a growth of 29.66 per cent in comparison to Rs 789.60 ...

Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings. Higher sales of Mirabegron and new launches led ...

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value ...

Zydus Lifesciences Ltd share price was up by -1.05% from the previous closing price of ₹974.00. Who are peers of Zydus Lifesciences Ltd? The peers of Zydus Lifesciences Ltd are Sun ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

For FMCG companies, rural India has become the new frontier. As consumption in rural areas grows at a faster pace than in urban markets, companies are ramping up their efforts to tap into this ...

Ethereum, Filecoin, Chainlink, and many other billion-dollar cryptocurrencies started with ICO campaigns, and we all know how far they’ve come in terms of performance and value. Any of the coins ...

Zydus Wellness Ltd. is a Public Limited Listed company incorporated on 01/11/1994 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is ...

Zydus Lifesciences has been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b trial testing its experimental oral treatment usnoflast in people with amyotrophic lateral ...